Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A: Modulation of P-glycoprotein function

Andrea Picchianti Diamanti, Manuela Rosado, Valentina Germano, Marco Scarsella, Ezio Giorda, Edoardo Podestà, Raffaele D'Amelio, Rita Carsetti, Bruno Laganà

Research output: Contribution to journalArticle

Abstract

Secondary resistance may be a major problem in the management of autoimmune diseases. P-glycoprotein (P-gp) over-function has been described as a mechanism of drug resistance in autoimmune patients. P-gp function can in vitro be inhibited by cyclosporine A (CSA) and verapamil; moreover, P-gp reduction by CSA in systemic lupus erythematosus and rheumatoid arthritis has been demonstrated. Here, P-gp function before and after CSA administration in three psoriatic arthritis (PsA) patients, who developed a resistance to MTX/SSA, has been evaluated. P-gp function on patient cells was analyzed by measuring the changes in rhodamine-123 (Rh-123) fluorescence after verapamil incubation. CSA treatment resulted in good clinical outcome that was related with a significant P-gp function reduction at CD3+ and CD8+ levels. In addition to its immunosuppressive activity, CSA results may also be related to MTX/SSA effect restoration through P-gp inhibition. This is the first time that CSA has been demonstrated as being able to revert MTX/SSA resistance in PsA.

Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalClinical Immunology
Volume138
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Psoriatic Arthritis
P-Glycoprotein
Immunosuppressive Agents
Cyclosporine
Verapamil
Rhodamine 123
Drug Resistance
Systemic Lupus Erythematosus
Autoimmune Diseases
Rheumatoid Arthritis
Fluorescence

Keywords

  • Cyclosporine
  • Drug resistance
  • P-glycoprotein
  • Rhodamine-123

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A : Modulation of P-glycoprotein function. / Diamanti, Andrea Picchianti; Rosado, Manuela; Germano, Valentina; Scarsella, Marco; Giorda, Ezio; Podestà, Edoardo; D'Amelio, Raffaele; Carsetti, Rita; Laganà, Bruno.

In: Clinical Immunology, Vol. 138, No. 1, 01.2011, p. 9-13.

Research output: Contribution to journalArticle

Diamanti, Andrea Picchianti ; Rosado, Manuela ; Germano, Valentina ; Scarsella, Marco ; Giorda, Ezio ; Podestà, Edoardo ; D'Amelio, Raffaele ; Carsetti, Rita ; Laganà, Bruno. / Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A : Modulation of P-glycoprotein function. In: Clinical Immunology. 2011 ; Vol. 138, No. 1. pp. 9-13.
@article{4891d67ef9d14a5d838c90e1600a2671,
title = "Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A: Modulation of P-glycoprotein function",
abstract = "Secondary resistance may be a major problem in the management of autoimmune diseases. P-glycoprotein (P-gp) over-function has been described as a mechanism of drug resistance in autoimmune patients. P-gp function can in vitro be inhibited by cyclosporine A (CSA) and verapamil; moreover, P-gp reduction by CSA in systemic lupus erythematosus and rheumatoid arthritis has been demonstrated. Here, P-gp function before and after CSA administration in three psoriatic arthritis (PsA) patients, who developed a resistance to MTX/SSA, has been evaluated. P-gp function on patient cells was analyzed by measuring the changes in rhodamine-123 (Rh-123) fluorescence after verapamil incubation. CSA treatment resulted in good clinical outcome that was related with a significant P-gp function reduction at CD3+ and CD8+ levels. In addition to its immunosuppressive activity, CSA results may also be related to MTX/SSA effect restoration through P-gp inhibition. This is the first time that CSA has been demonstrated as being able to revert MTX/SSA resistance in PsA.",
keywords = "Cyclosporine, Drug resistance, P-glycoprotein, Rhodamine-123",
author = "Diamanti, {Andrea Picchianti} and Manuela Rosado and Valentina Germano and Marco Scarsella and Ezio Giorda and Edoardo Podest{\`a} and Raffaele D'Amelio and Rita Carsetti and Bruno Lagan{\`a}",
year = "2011",
month = "1",
doi = "10.1016/j.clim.2010.10.001",
language = "English",
volume = "138",
pages = "9--13",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A

T2 - Modulation of P-glycoprotein function

AU - Diamanti, Andrea Picchianti

AU - Rosado, Manuela

AU - Germano, Valentina

AU - Scarsella, Marco

AU - Giorda, Ezio

AU - Podestà, Edoardo

AU - D'Amelio, Raffaele

AU - Carsetti, Rita

AU - Laganà, Bruno

PY - 2011/1

Y1 - 2011/1

N2 - Secondary resistance may be a major problem in the management of autoimmune diseases. P-glycoprotein (P-gp) over-function has been described as a mechanism of drug resistance in autoimmune patients. P-gp function can in vitro be inhibited by cyclosporine A (CSA) and verapamil; moreover, P-gp reduction by CSA in systemic lupus erythematosus and rheumatoid arthritis has been demonstrated. Here, P-gp function before and after CSA administration in three psoriatic arthritis (PsA) patients, who developed a resistance to MTX/SSA, has been evaluated. P-gp function on patient cells was analyzed by measuring the changes in rhodamine-123 (Rh-123) fluorescence after verapamil incubation. CSA treatment resulted in good clinical outcome that was related with a significant P-gp function reduction at CD3+ and CD8+ levels. In addition to its immunosuppressive activity, CSA results may also be related to MTX/SSA effect restoration through P-gp inhibition. This is the first time that CSA has been demonstrated as being able to revert MTX/SSA resistance in PsA.

AB - Secondary resistance may be a major problem in the management of autoimmune diseases. P-glycoprotein (P-gp) over-function has been described as a mechanism of drug resistance in autoimmune patients. P-gp function can in vitro be inhibited by cyclosporine A (CSA) and verapamil; moreover, P-gp reduction by CSA in systemic lupus erythematosus and rheumatoid arthritis has been demonstrated. Here, P-gp function before and after CSA administration in three psoriatic arthritis (PsA) patients, who developed a resistance to MTX/SSA, has been evaluated. P-gp function on patient cells was analyzed by measuring the changes in rhodamine-123 (Rh-123) fluorescence after verapamil incubation. CSA treatment resulted in good clinical outcome that was related with a significant P-gp function reduction at CD3+ and CD8+ levels. In addition to its immunosuppressive activity, CSA results may also be related to MTX/SSA effect restoration through P-gp inhibition. This is the first time that CSA has been demonstrated as being able to revert MTX/SSA resistance in PsA.

KW - Cyclosporine

KW - Drug resistance

KW - P-glycoprotein

KW - Rhodamine-123

UR - http://www.scopus.com/inward/record.url?scp=78651350296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651350296&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2010.10.001

DO - 10.1016/j.clim.2010.10.001

M3 - Article

C2 - 21062675

AN - SCOPUS:78651350296

VL - 138

SP - 9

EP - 13

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -